Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor α agents

Background: Inhibitors of tumor necrosis factor α (TNFα) have demonstrated significant efficacy in chronic inflammatory diseases, including Crohn's disease (CD). To further elucidate the mechanisms of action of these agents, we compared the anti‐TNFα agents certolizumab pegol, infliximab, adali...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammatory bowel diseases 2007-11, Vol.13 (11), p.1323-1332
Hauptverfasser:	Nesbitt, Andrew, Fossati, Gianluca, Bergin, Marianne, Stephens, Paul, Stephens, Sue, Foulkes, Roly, Brown, Derek, Robinson, Martyn, Bourne, Tim
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Anti-Inflammatory Agents - pharmacology Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Apoptosis - drug effects Blood Cells Cells, Cultured Certolizumab Pegol Drug Evaluation Etanercept Granulocytes - drug effects Humans Immunoglobulin Fab Fragments - pharmacology Immunoglobulin G - pharmacology Inflammatory Bowel Diseases - drug therapy Infliximab Interleukin-1beta - biosynthesis Lipopolysaccharides - pharmacology Lymphocytes - cytology Lymphocytes - drug effects Monocytes Polyethylene Glycols - pharmacology Receptors, Tumor Necrosis Factor TNFα Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!